Suppressing somatostatin

How Zucara's SSTR2 antagonists could prevent hypoglycemia in T1D patients

Zucara Therapeutics Inc. is developing somatostatin receptor 2 antagonists to prevent hypoglycemia in Type I diabetes patients without decreasing the efficacy of insulin therapy.

In Type I diabetes, somatostatin production is elevated, leading to continuous inhibition of glucagon. Glucagon inhibition in turn prevents patients from increasing and normalizing blood glucose levels following insulin therapy.

Hypoglycemia is addressed with rescue injections of glucose or

Read the full 638 word article

User Sign In